Domestically produced novel drugs accounted for more than 80 per cent of market approvals in China in the first half of the year, reflecting a “leap” in the quality of the country’s pharmaceutical innovation, according to a government spokesman. A total of 38 innovative drugs were cleared for sale in the six-month period, of which 31 were home-grown medicines, said Ministry of Industry and Information Technology spokesman Tao Qing, at a media briefing in Beijing on Monday. The approvals, along...
Back to Business
Business
July 20, 2026 at 11:00 AM
‘Systemic leap’: China’s drug innovation push yields bumper crop
SCMP Business